Intercure Ltd. (INCR) — 6-K Filings

6-K Filings (21)

• 6-K Filing — Dec 30, 2025
• 6-K Filing — Dec 18, 2025
• 6-K Filing — Nov 25, 2025
• InterCure & Cannasoul Forge Cannabis Science Partnership — Nov 3, 2025 Risk: medium
  On November 3, 2025, InterCure Ltd. announced a strategic investment and collaboration with Cannasoul to advance cannabis science and pharmaceutical innovation.
• InterCure Reports H1 2025 Results: NIS 130M Revenue — Oct 8, 2025 Risk: medium
  InterCure Ltd. reported its first half 2025 results on October 8, 2025, with revenues reaching NIS 130 million and positive operating cash flow. The company fil
• InterCure to Acquire ISHI in Two-Phase Deal — Sep 19, 2025 Risk: medium
  On September 17, 2025, InterCure Ltd. entered into a share purchase agreement to acquire 100% of ISHI (Botanico Ltd.), an Israeli cannabis company, in a two-pha
• InterCure Ltd. Announces Board Leadership Change — Feb 13, 2025 Risk: medium
  InterCure Ltd. announced on February 12, 2025, that Ehud Barak will step down as Chairman of the Board effective February 13, 2025. He will be succeeded by Alex
• Intercure Ltd. Shareholder Meeting Approves Key Proposal — Feb 3, 2025 Risk: low
  On February 3, 2025, Intercure Ltd. held an Extraordinary General Meeting of Shareholders where a proposal, previously outlined in a December 20, 2024 notice, w
• Intercure Ltd. Shareholder Meeting Adjourned Due to Lack of Quorum — Jan 27, 2025 Risk: medium
  Intercure Ltd. convened an extraordinary general meeting of shareholders on January 27, 2025, but it was adjourned for one week due to a lack of quorum. The mee
• Intercure Ltd. Shareholder Meeting Approves All Proposals — Dec 30, 2024 Risk: low
  On December 30, 2024, Intercure Ltd. held its Annual General Meeting of Shareholders where all five proposals presented were approved. These proposals were prev
• InterCure Ltd. Secures Up to $29.8M in Funding — Dec 20, 2024 Risk: medium
  On December 19, 2024, InterCure Ltd. secured funding commitments totaling NIS 66 million (approximately USD 18.2 million), with the potential to increase to NIS
• Intercure Ltd. Sets Shareholder Meeting for Dec 30 — Nov 25, 2024 Risk: low
  Intercure Ltd. announced on November 25, 2024, that its Annual General Meeting of Shareholders will be held on December 30, 2024, at 4:00 p.m. Israel time. The
• Intercure Ltd. Shareholders Approve All 8 Proposals at EGM — Nov 4, 2024 Risk: low
  On November 4, 2024, Intercure Ltd. held an Extraordinary General Meeting of Shareholders where all eight proposals presented were approved. These proposals wer
• InterCure Ltd. Meeting Adjourned Due to Lack of Quorum — Oct 28, 2024 Risk: low
  InterCure Ltd. held an Extraordinary General Meeting of Shareholders on October 28, 2024, which was adjourned for one week due to a lack of quorum. The meeting
• Intercure Ltd. Schedules Extraordinary General Meeting — Sep 13, 2024 Risk: low
  Intercure Ltd. announced on September 13, 2024, that it will hold an Extraordinary General Meeting of Shareholders on October 28, 2024. The meeting will take pl
• Intercure Ltd. Reports H1 2024 Financial Results — Aug 29, 2024 Risk: low
  Intercure Ltd. announced its financial results for the six months ended June 30, 2024, via a press release on August 29, 2024. The company is a foreign private
• InterCure Expands Cookies Partnership to Germany — Aug 28, 2024 Risk: medium
  InterCure Ltd. announced on August 28, 2024, the expansion of its strategic partnership with Cookies to Germany. This move aims to introduce InterCure's pharmac
• InterCure Wins Class Action Lawsuit Dismissal — May 21, 2024 Risk: low
  InterCure Ltd. announced on May 21, 2024, that the Tel Aviv-Yafo District Court ruled in its favor, dismissing a class action lawsuit. The lawsuit had alleged m
• InterCure Reports Preliminary 2023 Revenue and EBITDA — Apr 1, 2024 Risk: medium
  InterCure Ltd. announced preliminary estimated 2023 revenue of NIS 351 million and EBITDA exceeding NIS 50 million. The company also reported that its second-ha
• Intercure COO Rami Levy Resigns Effective Feb 7 for Personal Reasons — Feb 13, 2024 Risk: low
  Rami Levy resigned as the Chief of Operations of Intercure Ltd. effective February 7, 2024, citing personal reasons. The company, Intercure Ltd., explicitly sta
• InterCure to Acquire Leon Cannabis Pharmacy Chain, Issuing 1.75M-1.84M Shares — Jan 31, 2024
  InterCure Ltd. (NASDAQ: INCR) announced on January 31, 2024, that it has signed a definitive agreement to acquire Leon Pharm Ltd., a prominent Israeli pharmacy

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX